Johanna Hamel
Director of the Neuromuscular Pathology Laboratory · University of Rochester Medicine
Credentials: · · · ·
History
PresentNeuromuscular Pathology Laboratory · University of Rochester Medicine
- 2005–2009
| Martin Luther Universitaet Halle Wittenberg (Germany).
Research
Facioscapulohumeral Muscular Dystrophy: Update on Pathogenesis and Future Treatments
Review · Neurotherapeutics · 2018 · First of 2 authors · Corresponding · 78 citations
Patient-Reported Symptoms in Facioscapulohumeral Muscular Dystrophy (PRISM-FSHD)
Neurology · 2019 · First of 7 authors · Corresponding · 70 citations
Fingolimod-associated PML in a patient with prior immunosuppression
Case report · Neurology · 2016 · 43 citations
9 papers
9 papers
8 papers · 3 as a fellow
6 papers
- NJ
5 papers
5 papers
4 papers
4 papers
Grants
- 2026–2030
Calcium Channel Blocker in Myotonic Dystrophy Type 1 (CAP DM1)
Food and Drug Administration · R01
Contact PI · $631.2K · University of Rochester
- 2024–2028
Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Center
National Institute of Neurological Disorders and Stroke · P50
Project lead · $1.4M · University of Florida
- 2023–2028
Pharmacodynamic Biomarker of Myotonic Dystrophy
National Institute of Neurological Disorders and Stroke · R61
PI · $822.8K · University of Rochester
Clinical trials
- 2023–2030
Remote Assessments and Genetic Determinants of Congenital and Childhood Myotonic Dystrophy
Principal investigator · Recruiting
University of Rochester
- 2022–2030
Remote Assessments and Genetic Determinants of Myotonic Dystrophy
Principal investigator · Recruiting
University of Rochester
- 2019–2026
Estab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1)
Site PI · Recruiting
Virginia Commonwealth University